--

7 (1) 2017

Effect of Plumbagin on growth inhibition and apoptosis of imatinib-resistant chronic myeloid leukemia


Author - Affiliation:
Bui Thi Kim Ly - Biotechnology Center of Ho Chi Minh City , Vietnam
Hoang Thanh Chi - Biotechnology Center of Ho Chi Minh City , Vietnam
Quach Ngo Diem Phuong - University of Science – VNU HCMC , Vietnam
Ho Bao Thuy Quyen - Ho Chi Minh City Open University , Vietnam
Corresponding author: Bui Thi Kim Ly - buithikimly1201@gmail.com

Abstract
Development of a new inhibitor of BCR-ABL tyrosine kinase is necessary for the treatment of chronic myeloid leukemia (CML) because of increasing resistance and tolerance to Imatinid efforts. Herein, we reported Plumbagin
can significantly inhibit the growth of CML. The results revealed that Plumbagin inhitbited TCCY and TCCY/T315I cells with IC50 values 3 μM and 2.1 μM, respectively. Plumbagin also showed anti-proliferative effects on both the wide type Ba/F3 and the BCR-ABL-transfected Ba/F3 cells with a range of IC50 from 3.2 to 3.8 μM. In addition, Plumbagin induced the apoptosis of CML cells. That would provide a new and potential drug as a chemotherapy medication in the treatment of Imatinid -resistant CML.

Keywords
Apoptosis; BCR-ABL/T315I; CML; Imatinib-resistance; Inhibition; Plumbagin.

Full Text:
PDF

References

Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, et al. (2006). Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A , 103, 16870-16875.


Jabbour E, Mathisen MS, O'Brien S. (2012). 10 years of progress in chronic myelogenous leukemia. J Natl Compr Canc Netw, 10, 1049-1053.


Kimura S, Ando T, Kojima K. (2014). Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol, 19, 3-9.


Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.


Chen R, Chen B. (2015). The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther, 9, 773-779.


Hafeez BB, Zhong W, Fischer JW, Mustafa A, Shi X, et al. (2013). Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3Mluciferase cells in an orthotopic xenograft mouse model. Mol Onco, l7, 428-439.


Ono T, Ota A, Ito K, Nakaoka T, Karnan S, et al. (2015). Plumbagin suppresses tumor cell growth in oral squamous cell carcinoma cell lines. Oral Dis, 21, 501-511.


Padhye S, Dandawate P, Yusufi M, Ahmad A, Sarkar FH. (2012). Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev, 32, 1131-1158.


Liu X, Cai W, Niu M, Chong Y, Liu H, et al. (2015). Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1. J Neurooncol, 121, 469-477.


Ly BT, Chi HT, Yamagishi M, Kano Y, Hara Y, et al. (2013). Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells. PLoS One, 8, e66378.


Luthra R, Sanchez-Vega B, Medeiros LJ. (2004). TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol, 17, 96-103.


Kawiak A, Zawacka-Pankau J, Lojkowska E. (2012). Plumbagin induces apoptosis in Her2-overexpressing breast cancer cells through the mitochondrial-mediated pathway. J Nat Prod, 75, 747-751.


Zhou ZW, Li XX, He ZX, Pan ST, Yang Y, et al. (2015). Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells. Drug Des Devel Ther, 9, 1511-1554.


Pan ST, Qin Y, Zhou ZW, He ZX, Zhang X, et al. (2015). Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells. Drug Des Devel Ther, 9, 1601-1626.



Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.